These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 24563541)

  • 1. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
    Condon SM; Mitsuuchi Y; Deng Y; LaPorte MG; Rippin SR; Haimowitz T; Alexander MD; Kumar PT; Hendi MS; Lee YH; Benetatos CA; Yu G; Kapoor GS; Neiman E; Seipel ME; Burns JM; Graham MA; McKinlay MA; Li X; Wang J; Shi Y; Feltham R; Bettjeman B; Cumming MH; Vince JE; Khan N; Silke J; Day CL; Chunduru SK
    J Med Chem; 2014 May; 57(9):3666-77. PubMed ID: 24684347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
    Deng Y; Haimowitz T; LaPorte MG; Rippin SR; Alexander MD; Kumar PT; Hendi MS; Lee YH; Condon SM
    ACS Med Chem Lett; 2016 Mar; 7(3):318-23. PubMed ID: 26985322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
    Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
    Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
    Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
    Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
    Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
    J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
    Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
    Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
    Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
    Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
    Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
    Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
    Cossu F; Malvezzi F; Canevari G; Mastrangelo E; Lecis D; Delia D; Seneci P; Scolastico C; Bolognesi M; Milani M
    Protein Sci; 2010 Dec; 19(12):2418-29. PubMed ID: 20954235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
    Darding M; Feltham R; Tenev T; Bianchi K; Benetatos C; Silke J; Meier P
    Cell Death Differ; 2011 Aug; 18(8):1376-86. PubMed ID: 21331077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.